PMID- 37946751
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231113
IS  - 2689-2812 (Electronic)
IS  - 2689-2812 (Linking)
VI  - 5
IP  - 4
DP  - 2023
TI  - Designing Anti-Viral Vaccines that Harness Intrastructural Help from Prior BCG 
      Vaccination.
PG  - 97-102
LID - 10.33696/immunology.5.174 [doi]
AB  - Vaccines are among the most effective tools for combatting the impact and spread 
      of infectious diseases. However, the effectiveness of a vaccine can be diminished 
      by vaccine inequality, particularly during severe outbreaks of infectious 
      diseases in resource-poor areas. As seen in many developing countries that lack 
      adequate healthcare infrastructure and economic resources, the acquisition and 
      distribution of potentially life-saving vaccines may be limited, leading to 
      prolonged suffering and increased deaths. To improve vaccine equity, vaccine 
      design must take into consideration the logistics needed to implement a 
      successful vaccination drive, particularly among the most vulnerable populations. 
      In the manuscript titled "Exploiting Pre-Existing CD4(+) T Cell Help from Bacille 
      Calmette-Guerin Vaccination to Improve Antiviral Antibody Responses" published in 
      the Journal of Immunology, the authors designed a recombinant subunit vaccine 
      against the Ebola virus (EBOV) glycoprotein that can harness the pre-existing T 
      helper cells from prior BCG vaccination. As a recombinant subunit vaccine 
      adjuvanted with alum, this approach has many features that make it well suited 
      for the design of vaccines for developing nations, such as relative ease of 
      production, scalability, and distribution. In addition, the high prevalence of 
      BCG immunization and natural immunity to mycobacteria in many regions of the 
      world endow such vaccines with features that should increase potency and efficacy 
      among populations residing in such regions. As a result of using the helper 
      activity of pre-existing BCG-specific Th cells to drive antibody responses, a 
      lower vaccine dose is needed, which is a major advantage for vaccine manufacture. 
      Furthermore, the BCG-specific Th cells also stimulate immunoglobulin class 
      switching to IgG isotypes that have strong affinities for activating Fc-gamma 
      receptors (FcgammaRs). Taken together, we propose that the design of subunit vaccines 
      with intrastructural help from BCG-specific Th cells can improve protection 
      against viral infection and represents a vaccine design that can be generally 
      adapted to other emerging viral pathogens for the control and prevention of 
      infection in many developing countries.
FAU - Ng, Tony W
AU  - Ng TW
AD  - Department of Microbiology and Immunology, Albert Einstein College of Medicine, 
      Bronx, NY10461, USA.
FAU - Porcelli, Steven A
AU  - Porcelli SA
AD  - Department of Microbiology and Immunology, Albert Einstein College of Medicine, 
      Bronx, NY10461, USA.
AD  - Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, 
      USA.
LA  - eng
GR  - R01 AI137344/AI/NIAID NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - J Cell Immunol
JT  - Journal of cellular immunology
JID - 101757237
PMC - PMC10635577
MID - NIHMS1939518
OTO - NOTNLM
OT  - Antibody
OT  - BCG
OT  - Intrastructural help
OT  - Linked recognition
OT  - Th cells
OT  - Vaccine
OT  - Virus
EDAT- 2023/11/10 06:45
MHDA- 2023/11/10 06:46
PMCR- 2023/11/09
CRDT- 2023/11/10 03:55
PHST- 2023/11/10 06:46 [medline]
PHST- 2023/11/10 06:45 [pubmed]
PHST- 2023/11/10 03:55 [entrez]
PHST- 2023/11/09 00:00 [pmc-release]
AID - 10.33696/immunology.5.174 [doi]
PST - ppublish
SO  - J Cell Immunol. 2023;5(4):97-102. doi: 10.33696/immunology.5.174.